1-8 of 8
Christoph Kapitza
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Effects of Lixisenatide Versus Liraglutide (Short- and Long-Acting GLP-1 Receptor Agonists) on Esophageal and Gastric Function in Patients With Type 2 Diabetes

Daniel R. Quast, Nina Schenker, Björn A. Menge, Michael A. Nauck, Christoph Kapitza, Juris J. Meier
Journal: Diabetes Care
Diabetes Care 2020;43(9):2137–2145
https://doi.org/10.2337/dc20-0720
Published: 09 July 2020
View article titled, Effects of Lixisenatide Versus Liraglutide (Short- and Long-Acting GLP-1 Receptor Agonists) on Esophageal and Gastric Function in Patients With Type 2 Diabetes
Open the PDF for Effects of Lixisenatide Versus Liraglutide (Short- and Long-Acting GLP-1 Receptor Agonists) on Esophageal and Gastric Function in Patients With Type 2 Diabetes in another window
Journal Articles

Accuracy and Longevity of an Implantable Continuous Glucose Sensor in the PRECISE Study: A 180-Day, Prospective, Multicenter, Pivotal Trial

Jort Kropff, Pratik Choudhary, Sankalpa Neupane, Katharine Barnard, Steve C. Bain, Christoph Kapitza, Thomas Forst, Manuela Link, Andrew Dehennis, J. Hans DeVries
Journal: Diabetes Care
Diabetes Care 2017;40(1):63–68
https://doi.org/10.2337/dc16-1525
Published: 04 November 2016
View article titled, Accuracy and Longevity of an Implantable Continuous Glucose Sensor in the PRECISE Study: A 180-Day, Prospective, Multicenter, Pivotal Trial
Open the PDF for Accuracy and Longevity of an Implantable Continuous Glucose Sensor in the PRECISE Study: A 180-Day, Prospective, Multicenter, Pivotal Trial in another window
Includes: Supplementary data
Journal Articles

Contrasting Effects of Lixisenatide and Liraglutide on Postprandial Glycemic Control, Gastric Emptying, and Safety Parameters in Patients With Type 2 Diabetes on Optimized Insulin Glargine With or Without Metformin: A Randomized, Open-Label Trial

Juris J. Meier, Julio Rosenstock, Agnès Hincelin-Méry, Christine Roy-Duval, Astrid Delfolie, Hans-Veit Coester, Bjoern A. Menge, Thomas Forst, Christoph Kapitza
Journal: Diabetes Care
Diabetes Care 2015;38(7):1263–1273
https://doi.org/10.2337/dc14-1984
Published: 17 April 2015
View article titled, Contrasting Effects of Lixisenatide and Liraglutide on Postprandial Glycemic Control, Gastric Emptying, and Safety Parameters in Patients With Type 2 Diabetes on Optimized Insulin Glargine With or Without Metformin: A Randomized, Open-Label Trial
Open the PDF for Contrasting Effects of Lixisenatide and Liraglutide on Postprandial Glycemic Control, Gastric Emptying, and Safety Parameters in Patients With Type 2 Diabetes on Optimized Insulin Glargine With or Without Metformin: A Randomized, Open-Label Trial in another window
Includes: Supplementary data
Journal Articles

Further Improvement in Postprandial Glucose Control With Addition of Exenatide or Sitagliptin to Combination Therapy With Insulin Glargine and Metformin: A proof-of-concept study

Sabine Arnolds, MD, Sibylle Dellweg, MD, Janina Clair, MD, Marie-Paule Dain, MD, Michael A. Nauck, MD, Klaus Rave, MD, Christoph Kapitza, MD
Journal: Diabetes Care
Diabetes Care 2010;33(7):1509–1515
https://doi.org/10.2337/dc09-2191
Published: 31 March 2010
View article titled, Further Improvement in Postprandial Glucose Control With Addition of Exenatide or Sitagliptin to Combination Therapy With Insulin Glargine and Metformin: <subtitle>A proof-of-concept study</subtitle>
Open the PDF for Further Improvement in Postprandial Glucose Control With Addition of Exenatide or Sitagliptin to Combination Therapy With Insulin Glargine and Metformin: <subtitle>A proof-of-concept study</subtitle> in another window
Journal Articles

Oral Insulin: A Comparison With Subcutaneous Regular Human Insulin in Patients With Type 2 Diabetes

Christoph Kapitza, MD, Eric Zijlstra, PHD, Lutz Heinemann, PHD, M. Cristina Castelli, PHD, Gary Riley, DVM, PHD, Tim Heise, MD
Journal: Diabetes Care
Diabetes Care 2010;33(6):1288–1290
https://doi.org/10.2337/dc09-1807
Published: 25 February 2010
View article titled, Oral Insulin: A Comparison With Subcutaneous Regular Human Insulin in Patients With Type 2 Diabetes
Open the PDF for Oral Insulin: A Comparison With Subcutaneous Regular Human Insulin in Patients With Type 2 Diabetes in another window
Includes: Supplementary data
Journal Articles

Changes in Basal Insulin Infusion Rates With Subcutaneous Insulin Infusion: Time until a change in metabolic effect is induced in patients with type 1 diabetes

Lutz Heinemann, PHD, Leszek Nosek, MD, Christoph Kapitza, MD, Matthias-Axel Schweitzer, MD, Lars Krinelke, MD
Journal: Diabetes Care
Diabetes Care 2009;32(8):1437–1439
https://doi.org/10.2337/dc09-0595
Published: 01 June 2009
View article titled, Changes in Basal Insulin Infusion Rates With Subcutaneous Insulin Infusion: <subtitle>Time until a change in metabolic effect is induced in patients with type 1 diabetes</subtitle>
Open the PDF for Changes in Basal Insulin Infusion Rates With Subcutaneous Insulin Infusion: <subtitle>Time until a change in metabolic effect is induced in patients with type 1 diabetes</subtitle> in another window
Journal Articles

Treatment With the Human Once-Weekly Glucagon-Like Peptide-1 Analog Taspoglutide in Combination With Metformin Improves Glycemic Control and Lowers Body Weight in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Alone: A double-blind placebo-controlled study

Michael A. Nauck, MD, Robert E. Ratner, MD, Christoph Kapitza, MD, Rachele Berria, MD, Mark Boldrin, Raffaella Balena, MD, PHD
Journal: Diabetes Care
Diabetes Care 2009;32(7):1237–1243
https://doi.org/10.2337/dc08-1961
Published: 14 April 2009
View article titled, Treatment With the Human Once-Weekly Glucagon-Like Peptide-1 Analog Taspoglutide in Combination With Metformin Improves Glycemic Control and Lowers Body Weight in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Alone: <subtitle>A double-blind placebo-controlled study</subtitle>
Open the PDF for Treatment With the Human Once-Weekly Glucagon-Like Peptide-1 Analog Taspoglutide in Combination With Metformin Improves Glycemic Control and Lowers Body Weight in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Alone: <subtitle>A double-blind placebo-controlled study</subtitle> in another window
Includes: Supplementary data
Journal Articles

Absorption and Metabolic Effect of Inhaled Insulin: Intrapatient variability after inhalation via the Aerodose Insulin Inhaler in patients with type 2 diabetes

Ayesh D. Perera, PHD, Christoph Kapitza, MD, Leszek Nosek, MD, Robert S. Fishman, MD, David A. Shapiro, MD, Tim Heise, MD, Lutz Heinemann, PHD
Journal: Diabetes Care
Diabetes Care 2002;25(12):2276–2281
https://doi.org/10.2337/diacare.25.12.2276
Published: 01 December 2002
View article titled, Absorption and Metabolic Effect of Inhaled Insulin: <subtitle>Intrapatient variability after inhalation via the Aerodose Insulin Inhaler in patients with type 2 diabetes</subtitle>
Open the PDF for Absorption and Metabolic Effect of Inhaled Insulin: <subtitle>Intrapatient variability after inhalation via the Aerodose Insulin Inhaler in patients with type 2 diabetes</subtitle> in another window